DDW 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

DDW 2022 Conference Coverage

Videos

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Efficacy and Safety of Mirikizumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From The Phase 3 LUCENT-2 Study

By DDW 2022 Conference Coverage FEATURING Marla Dubinsky

0 views

June 29, 2022

Mirikizumab was approved by the FDA on October 26, 2023

Comments 0

Patient Cases: Making Treatment Decisions in IBS-C

Feat. D. M. Brenner

Key Clinical Data From an IBS-C Treatment Option

Feat. B. Lacy

Videos